Navigation Links
Flow restrictors may reduce young children's accidental ingestion of liquid medications
Date:7/24/2013

Cincinnati, OH -- In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising. In a new study scheduled for publication in The Journal of Pediatrics, researchers studied whether adding flow restrictors to bottles can limit the amount of liquid medication a child could access even if child-resistant caps are missing or improperly closed.

Standard child-resistant packaging is designed to prevent or delay young children from opening bottles, giving caregivers reasonable time to intervene. However, in order for the packaging to work effectively, "Caregivers must correctly resecure the cap after each and every use. If the cap is not correctly resecured, children can open and drink whatever medication is in the bottle," according to Daniel S. Budnitz, MD, MPH, and colleagues from the Centers for Disease Control and Prevention, Emory University, and the Georgia Poison Center.

To address a potential second line of defense, the researchers studied whether flow restrictors (adapters added to the neck of a bottle to limit the release of liquid) had any effect on the ability of children to remove test liquid, as well as how much they were able to remove in a given amount of time. 110 children, aged 3-4 years, participated in two tests. In one test, the children were given an uncapped medication bottle with a flow restrictor, and in the other test, the children received either a traditional bottle without a cap or with an incompletely-closed child-resistant cap. For each test, children were given 10 minutes to remove as much test liquid as possible.

Within 2 minutes, 96% of bottles without caps and 82% of bottles with incompletely-closed caps were emptied. In contrast, none of the uncapped bottles with flow restrictors were emptied before 6 minutes, and only 6% of children were able to empty bottles with flow restrictors within the 10-minute test period. Overall, older children were more successful than younger children at removing liquid from the flow-resistant bottles. None of the youngest children (36-41 months) were able to remove 5 mL of test liquid, the amount in a standard dose of acetaminophen for a 2- to 3-year-old child.

Manufacturers voluntarily added flow restrictors to over-the-counter infant acetaminophen in 2011. Based on their effectiveness, the authors suggest that flow restrictors could be added to other liquid medications, especially those harmful in small doses. Importantly, according to study co-author Maribeth C. Lovegrove, MPH, "Flow restrictors are designed as a secondary barrier and caregivers should not rely on flow restrictors alone; adding flow restrictors could complement the safety provided by current child-resistant packaging." Caregiver education should continue to focus on consistently locking child-resistant caps and storing medications away and out of sight of children.


'/>"/>

Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Soy-based S-equol supplement reduces metabolic syndrome risk factors
2. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
3. ONR taps research teams to help reduce jet noise
4. Nanocrystal-coated fibers might reduce wasted energy
5. Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations
6. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
7. Tax on salt could reduce cardiovascular disease deaths by 3 percent
8. How the ecological risks of extended bioenergy production can be reduced
9. Laparoscopy reduces the risk of small-bowel obstruction
10. Researchers show prebiotic can reduce severity of colitis
11. CUNY Energy Institute battery system could reduce buildings electric bills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: